Target General Information
Target ID	T74312
Target Name	Receptor-type tyrosine-protein kinase (FLT3)
Gene Name	FLT3
Species	Homo sapiens
UniProt ID	FLT3_HUMAN
Sequence	MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESP EDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDL QNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQD ALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRE CTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEM STYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYE IDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHA ENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITE GVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQD NISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYD LKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMS ELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKE HNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDL NVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDS NYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYK LIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDG RVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS [Homo sapiens]
Drug and Corresponding Resistance Mutations
Mutation Info	Missense: D835F
Drugs	Drug Name Quizartinib Drug Info [3] Targeted Disease Acute Myeloid Leukaemia
Mutation Info	Missense: D835H
Drugs	Drug Name Sorafenib Drug Info [1], [5] Targeted Disease Acute Myeloid Leukaemia Mutation Prevalence 4 out of 13 patients
Mutation Info	Missense: D835V
Drugs	Drug Name Quizartinib Drug Info [3] Targeted Disease Acute Myeloid Leukaemia
Mutation Info	Missense: D835Y
Drugs	Drug Name Sunitinib Drug Info [1] Targeted Disease Acute Myeloid Leukaemia; Gastrointestinal Stromal Tumor Mutation Prevalence 1 out of 6 patients
	Drug Name Quizartinib Drug Info [2], [3] Targeted Disease Acute Myeloid Leukaemia
	Drug Name Sorafenib Drug Info [5] Targeted Disease Acute Myeloid Leukaemia
Mutation Info	Missense: F691L
Drugs	Drug Name Quizartinib Drug Info [3], [4] Targeted Disease Acute Myeloid Leukaemia
	Drug Name Sorafenib Drug Info [1] Targeted Disease Acute Myeloid Leukaemia Mutation Prevalence 2 out of 6 patients
References
REF 1	Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013 Oct 15;19(20):5758-68.
REF 2	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 2012 Jul;26(7):1462-70.
REF 3	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15;485(7397):260-3.
REF 4	The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013 Jun;27(6):1416-8.
REF 5	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012 May 31;119(22):5133-43.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.